The Applied DNA Sciences Inc. (NASDAQ:APDN) is going down by -1.23% in today’s trading session, a fall equivalent to -0.05% of the stock’s price from yesterday’s market close. A news came out on 11/15/19 stating that Applied DNA Sciences Announces Closing of Upsized $12.0 Million Underwritten Public Offering by WSJ. The lowest point that the shares touched during the trading session was $4.02, while the peak of the day was recorded at a share price of $4.3999. APDN finished the previous session at $4.07 according to the data provided by Barchart, while the trading volume was observed to be $539814.
In the 100 days of trading, APDN managed to top a 11.49% Moving average. Additionally, Applied DNA Sciences Inc. shares have achieved a 52-week range between 4.02 and 49.56 alongside 100 days raw stochastic set at 1.78%.
The number of shares outstanding, according to the fundamentals of the company, is set at 1.33M, equal to the value of $5.41M in market capitalization. In the last 30 days, Applied DNA Sciences Inc. shares went down by -79.48%, adding 19.69 to growth in value, on top of a +9.19% boost since 10/18/19.
Applied DNA Sciences Inc. (NASDAQ:APDN) Analyst’s Estimates
Applied DNA Sciences Inc. (APDN) could record at least $0.00 per share in quarterly earnings in the upcoming report on 12/13/2019, a number that would actually represent a decrease of -3.20 YOY.
According to the average analyst rating, Applied DNA Sciences Inc. would be rated as Hold. Out of 1 different analysts monitoring APDN stock, 0 analysts rate the stock as a BUY, 1 suggest to give the rating of HOLD, 0 indicate that APDN is an OVERWEIGHT, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.
On November 14, 2016, the stock earned a Reiterated rating due to a new analyst call from Maxim Group, while analysts from Maxim Group believe that the stock is set at Buy, as concluded on May 13, 2016. Maxim Group, is still rather wary about the stock, deciding to keep the rating at Buy as confirmed through a call on October 08, 2015.
Regardless of the rating, The Benchmark Company did increase their price to $5 as they are considering target share price analysis. Maxim Group, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on February 10, 2015, giving the stock a Buy rating.
APDN Key Ratios To Watch:
Taking in account the profitability of the Company, gross profit margin of +55.05% has been attained, while the operating margin has been recorded at -298.37%. The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -169.61%. Beta value of the stock is recorded at 0.25. Additionally, Applied DNA Sciences Inc. is recording price volatility of 61.47% for the period of the last seven days and 28.71% in the last 30 days.
Applied DNA Sciences Inc. (NASDAQ:APDN) Technical Outlook
For the period of the last 50 days, Applied DNA Sciences Inc. had its Raw Stochastic average set at 2.13% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 2.13%. Stochastic %K for Applied DNA Sciences Inc., with the last 20 days included, was set at 1.31%, having Stochastic %D topping 2.55%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be discouraging for Applied DNA Sciences Inc. stocks with recording -74.56% in metrics.
Applied DNA Sciences Inc. Insider Watch:
Similarly, 6.59% of the company’s float is held by institutions – and there are 36 institutions in total holding shares of this company. The top three institutional holders of APDN stocks are: Vanguard Group, Inc. (The) with ownership of $110024.0, which is approximately 12307 of the company’s shares; Taurus Asset Management, LLC, holding 10000 shares of the stock with an approximate value of $89400.0; and Chase Investment Counsel Corp, currently with more than 6529 shares of the company valued at $58369.0. Positions in Applied DNA Sciences Inc. stocks held by institutional investors has been changing actively in the past six months, a period during which there were 19 insider purchases amounting to 7262821 shares.